Abraxis BioScience, Inc., an integrated biotechnology company, today announced that the European Commission has granted marketing approval for ABRAXANE powder for suspension for infusion (an albumin-bound nanoparticle formulation of paclitaxel) for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.
Applied DNA Sciences, Inc. announced that it has filed multiple patent applications to cover its latest developments in optical reporter markers. These reporters 'announce' the presence of the DNA markers to which they are attached.
Nanostellar CEO Pankaj Dhingra will join a list of distinguished panelists at the World Economic Form in Davos, Switzerland, to address the entrepreneurial opportunities created by global warming. The panel, which takes place January 24, 2008, will turn its attention to the opportunities that the development and growth of 'green' initiatives can play in job creation and economic stimulation.
Molecular Profiles, a global leader in the provision of innovative contract research services to the pharmaceutical, biopharmaceutical and biomedical sectors, announces the latest addition to its comprehensive nanoscale analytical services offering, nanoPASSTM (nanoscale Predictive Analytical Screening Solution).
NanoViricides, Inc. reported today that they are on course with the development of nanoviricides drug candidates against highly pathogenic avian influenzas (HPAI) including H5N1 bird flu, and common influenza.
Arrowhead Research Corporation announced today that its President & CEO, Dr. Christopher Anzalone, will present at the 7th Annual Rice Alliance Nanotechnology Forum on January 24, 2008 at 4:00 pm CT in Houston, Texas.
A new white paper examines Neutron Activation Analysis (NAA) as a means for testing contaminant levels for healthcare solutions based on nanotechnology. The white paper, posted on ElementalAnalysis.com, discusses how NAA tests exhibit accuracies up to parts per quadrillion.
According to a new technical market research report from BCC Research, the Chinese market for advanced materials was worth $30.5 billion in 2007. This is expected to increase to over $60.5 billion by 2012, a compound average annual growth rate (CAGR) of 14.7%.
BioAlliance Pharma SA has announced its financial calendar for 2008, which notably includes the publication dates for its revenue statements and half-year and annual accounts, as well as the date of its shareholders' Annual General Meeting:
NanoTechnologies (U.K.), a Sedgefield-based developer and manufacturer of nanotechnology air-monitoring equipment, such as 'sniffer machines' for detecting airborne contaminates including biochemicals, biological agents and explosives, said Monday that it has appointed W H Ireland Corporate Finance as broker.
Dolomite has announced that its microfluidic device fabrication expertise is being used by automated laboratory equipment specialist, Syrris Ltd, within its novel range of flow reactor instruments. These microfluidic flow reactor modules supplied by Dolomite, enable the fast and efficient processing of chemicals for test and analysis.